Passage Bio, Inc. (PASG)
NCM – Real Time Price. Currency in USD
6.38
-0.51 (-7.40%)
At close: Mar 27, 2026, 4:00 PM EDT
6.21
-0.17 (-2.66%)
After-hours: Mar 27, 2026, 5:36 PM EDT

NCM – Real Time Price. Currency in USD
6.38
-0.51 (-7.40%)
At close: Mar 27, 2026, 4:00 PM EDT
6.21
-0.17 (-2.66%)
After-hours: Mar 27, 2026, 5:36 PM EDT
Passage Bio, Inc., a genetic medicines company, develops gene therapies for central nervous system diseases. It develops PBFT02, a functional granulin (GRN) and gene encoding progranulin (PGRN) for the treatment of FTD caused by progranulin deficiency; PBGM01, a functional GLB1 gene encoding β-galactosidase for infantile GM1; and PBKR03, for the treatment of Krabbe disease. The company develops PBML04 for the treatment of metachromatic leukodystrophy; PBAL05 for the treatment of amyotrophic lateral sclerosis; and other programs for huntington’s disease. It has a strategic research collaboration with the Trustees of the University of Pennsylvania’s Gene Therapy Program; and collaboration agreement, and a development services and clinical supply agreement with Catalent Maryland, Inc. Passage Bio, Inc. was incorporated in 2017 and is based in Philadelphia, Pennsylvania.
| Name | Position |
|---|---|
| Dr. Karl Whitney Ph.D. | Senior Vice President of Global Regulatory Affairs |
| Dr. Sue Browne Ph.D. | Chief Scientific Officer |
| Dr. William Chou M.D. | President, CEO & Director |
| Mr. Eden Fucci | Senior Vice President of Technical Operations |
| Mr. Stuart M. Henderson | Chief Business Officer |
| Ms. Kathleen Borthwick | Senior VP, CFO, Principal Financial Officer & Principal Accounting Officer |
| Date | Type | Document |
|---|---|---|
| 2026-03-10 | 8-K | tm268398d1_8k.htm |
| 2026-03-04 | S-8 | tm267647d1_s8.htm |
| 2026-03-03 | 8-K | pasg-20260303x8k.htm |
| 2026-01-12 | 8-K | tm262847d1_8k.htm |
| 2025-11-10 | 10-Q | pasg-20250930x10q.htm |
| 2025-09-18 | 8-K | tm2526408d1_8k.htm |
| 2025-08-12 | 10-Q | pasg-20250630x10q.htm |
| 2025-07-29 | 8-K | tm2521926d1_8k.htm |
| 2025-07-14 | 8-K | tm2520584d1_8k.htm |
| 2025-06-23 | 8-K | tm2518584d1_8k.htm |